港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

生物医药B类股

557.223

+22.3754.18%

涨家数：24

跌家数：8

平家数：2

市盈率：- -

高：561.530

开：534.650

低：532.866

收：534.848

数据加载中...

总览新闻资讯

创新药再度领涨

每日经济新闻

四环医药：跨越制药边界成就美与创新

科望医药无商业化三年亏17亿：创始人年薪千万，负债率超500%

国泰海通证券：持续推荐创新药加大对Pharma的推荐

开源证券医药|创新药黄金赛道：PD-1/VEGF 双抗有望成为千亿美金市场的基石用药

百济人均710万、诺诚健华人均309万，创新药“销冠”2024年集体升级

【渤健中国：渐冻症精准治疗药物托夫生注射液在中国商业上市】6月10日，渤健中国宣布，创新药物托夫生注射液正式在中国商业上市，意味着我国符合条件的渐冻症患者即将有机会用上这款创新药物。作为全球首个获批的肌萎缩侧索硬化精准治疗药物，托夫生注射液于去年9月在中国获批，用于治疗携带超氧化物歧化酶1基因突变的肌萎缩侧索硬化成人患者。

有“泡沫”？创新药主线飙升有人在减持和清仓

21世纪经济报道

安士制药（中山）有限公司申请III类会议

连云港职业技术学院打造智能制药人才新高地

【新股IPO】广州银诺医药集团股份有限公司向港交所主板提交上市申请

紧跟医药新零售，药师帮抢先布局“AI、机器人”医药场景

21世纪经济报道

万春医药上涨22.88%，报2.089美元/股，总市值8422.08万美元

中国抗体-B(03681)：独立非执行董事Dylan Carlo TINKER离世

美股异动 | 百济神州(ONC.US)涨逾4% 机构：创新药有望迎来价值重估

恒瑞医药HER2 ADC创新药注射用瑞康曲妥珠单抗全国首批发货

创新药持续火爆，“吃药”行情后市怎么看？

争议最大的国产创新药九期一，已经停工停产

6月9日鹏华医药科技股票A净值增长5.27%，今年来累计上涨64.8%

A股创新药板块走强产业或迎爆发式增长

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK1574/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":557.22327,"timestamp":1749542910677,"preClose":534.8484,"halted":0,"volume":296752405,"delay":0,"changeRate":0.041834,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":22.374878,"latestTime":"06-10 16:00:00","open":534.64966,"high":561.53046,"low":532.8655,"amount":6842878404,"amplitude":0.053595,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1749605400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749519000000,1749528000000],[1749531600000,1749542400000]],"pbRate":4.413457,"peRate":-27.18022,"turnoverRate":0.011177,"increases":24,"decrements":5,"flats":4,"marketCap":323938341120,"floatMarketCap":298441848048},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":561.53046,"amplitude":0.053595,"preClose":534.8484,"low":532.8655,"pbRate":"4.413457","latestPrice":557.22327,"volume":296752405,"delay":0,"open":534.64966,"prevYearClose":331.1933,"prevWeekClose":504.495,"prevMonthClose":491.683,"prevQuarterClose":455.082,"fiveDayClose":491.473,"twentyDayClose":447.877,"sixtyDayClose":422.518,"secType":"PLATE","market":"HK","turnoverRate":0.011177,"peRate":-27.18022,"marketCap":323938341120,"floatMarketCap":298441848048,"timestamp":1749542910677,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":24,"down":8,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542735198","title":"创新药再度领涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2542735198","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542735198?lang=zh_cn&edition=fundamental","pubTime":"2025-06-10 08:51","pubTimestamp":1749516713,"startTime":"0","endTime":"0","summary":"信达生物、迪哲医药、科伦博泰、泽璟制药、中国生物制药等公司的优质创新药品种发布数据。从今年的AACR和ASCO两项会议可以看出，中国创新药在新靶点、新技术、新疾病领域的布局已呈现领先趋势。中国创新药具备高效率、低成本的开发优势，当前在热门技术赛道如ADC、双抗、细胞治疗等已经具备竞争优势，有望持续展现行业竞争力。此外，国际化方面，中国创新药“出海”进程显著提速。展望未来，创新药有望迎来价值重估。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025061008540897789577&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025061008540897789577&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1191","IE00BZ08YS42.EUR","01177","BK1589","688331","01801","BK1521","BK1574","09995","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","01530","BK1161","BK1515"],"gpt_icon":0},{"id":"2542516213","title":"四环医药：跨越制药边界 成就美与创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2542516213","media":"华福证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542516213?lang=zh_cn&edition=fundamental","pubTime":"2025-06-10 08:36","pubTimestamp":1749515761,"startTime":"0","endTime":"0","summary":"以制药企业的严谨与创新，打造中国领先医美及生物制药企业。四环医药坚持“医美+创新药”的双轮驱动战略，成功实现转型升级。旗下子公司轩竹生物储备多款在研创新药产品，后续上市有望贡献业绩增量，可持续关注商业化兑现进度。我们选取医美、仿制药和创新药赛道的代表性公司作为估值参考，首次覆盖给予“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610083604a7014682&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610083604a7014682&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1600","01477","BK1515","BK1191","00460","BK1574","BK1593"],"gpt_icon":0},{"id":"2542176354","title":"科望医药无商业化三年亏17亿：创始人年薪千万，负债率超500%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542176354","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542176354?lang=zh_cn&edition=fundamental","pubTime":"2025-06-10 08:21","pubTimestamp":1749514860,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　日前，科望医药集团二度递表港交所。2024年6月公司首次向港交所递交上市申请，但因未在6个月内通过聆讯，申请失效。　　然而，公司目前尚无批准商业销售的产品，2022年至2024年三年合计亏损17.12亿元。截至2024年末，公司可转换可赎回优先股的账面价值超32亿元，负债净额超27亿元，现金流出现较大下滑态势，引发市场关注。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/stockzmt/2025-06-10/doc-inezpyws9146010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1574","159938","09939","BK1161"],"gpt_icon":0},{"id":"2542356000","title":"国泰海通证券：持续推荐创新药 加大对Pharma的推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2542356000","media":"东方财富","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542356000?lang=zh_cn&edition=fundamental","pubTime":"2025-06-10 08:04","pubTimestamp":1749513862,"startTime":"0","endTime":"0","summary":"国泰海通证券研报表示，近期BD催化不断，创新药出海逻辑稳健，行情有望持续。持续推荐创新药，同时加大对Pharma的推荐。创新药高景气，持续推荐价值有望迎来重估的仿转创Pharma；持续推荐创新管线逐步兑现、业绩进入放量期的Biopharma/Biotech；推荐盈利增速拐点逐渐体现的CXO。2025年6月第一周A股医药板块表现与大盘相当。截至2025年6月6日，医药板块相对于全部A股的溢价水平目前处于正常水平，当前相对溢价率86.84%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506100804249778855d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506100804249778855d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1147","BK1161","06978","BK1564","601211","03692","BK1574","02611"],"gpt_icon":0},{"id":"2542359667","title":"开源证券医药|创新药黄金赛道：PD-1/VEGF 双抗有望成为千亿美金市场的基石用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2542359667","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542359667?lang=zh_cn&edition=fundamental","pubTime":"2025-06-10 08:00","pubTimestamp":1749513600,"startTime":"0","endTime":"0","summary":"　　近期，开源证券医药团队发布行业深度报告《PD-1/VEGF 双抗有望成为千亿美金市场的基石用药》，聚焦2025 年PD-1/VEGF双抗赛道重大进展，深入分析国内外药企布局动向，带您把握国产创新药领域投资机会。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-06-10/doc-inezpuqu9263580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SGCmain","MGCmain","GCmain","159938","BK4023","NUGT","LU1169589451.USD","1OZmain","BK1515","159934","IAU","159992","SGUmain","518880","LU1169590202.USD","06978","09939","159831","161027","BK1161","PD","DUST","GDX","BK1574"],"gpt_icon":1},{"id":"2542356627","title":"百济人均710万、诺诚健华人均309万，创新药“销冠”2024年集体升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2542356627","media":"医药魔方","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542356627?lang=zh_cn&edition=fundamental","pubTime":"2025-06-10 07:57","pubTimestamp":1749513438,"startTime":"0","endTime":"0","summary":"人均300万，是创新药商业化效率的“金标准”，也是企业在一款药上实现盈利的底线。2024年，百济神州继续登顶，并且直接将销售人效直接拉升至710万，一骑绝尘；去年同样排行第三的诺诚健华，今年紧随其后，成为港股第三个迈过300万门槛的创新药企。2024年，百济神州产品收入38亿美元，同比增长74%。诺诚健华在2024年报中表示：随着复发难治MZL适应症的扩大以及复发难治CLL/SLL、复发难治MCL续约国家医保目录，宜诺凯2024年收入达10亿元里程碑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610080004a4a10744&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610080004a4a10744&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2542356840","title":"【渤健中国：渐冻症精准治疗药物托夫生注射液在中国商业上市】6月10日，渤健中国宣布，创新药物托夫生注射液正式在中国商业上市，意味着我国符合条件的渐冻症患者即将有机会用上这款创新药物。作为全球首个获批的肌萎缩侧索硬化精准治疗药物，托夫生注射液于去年9月在中国获批，用于治疗携带超氧化物歧化酶1基因突变的肌萎缩侧索硬化成人患者。","url":"https://stock-news.laohu8.com/highlight/detail?id=2542356840","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542356840?lang=zh_cn&edition=fundamental","pubTime":"2025-06-10 07:31","pubTimestamp":1749511889,"startTime":"0","endTime":"0","summary":"6月10日，渤健中国宣布，创新药物托夫生注射液正式在中国商业上市，意味着我国符合条件的渐冻症患者即将有机会用上这款创新药物。作为全球首个获批的肌萎缩侧索硬化精准治疗药物，托夫生注射液于去年9月在中国获批，用于治疗携带超氧化物歧化酶1基因突变的肌萎缩侧索硬化成人患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/10073150958927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","159992","BK1161","06978"],"gpt_icon":0},{"id":"2542435074","title":"有“泡沫”？创新药主线飙升 有人在减持和清仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2542435074","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542435074?lang=zh_cn&edition=fundamental","pubTime":"2025-06-10 07:22","pubTimestamp":1749511365,"startTime":"0","endTime":"0","summary":"今年创新药行情火热。回调了四年之久的创新药主题基金大幅回血，年内回报领先的绩优基金大多重仓了创新药。与此同时，近期对于创新药板块“泡沫”的讨论引发了广泛关注。创新药基金大涨有人称，“中国创新药迎来DeepSeek时刻”。万德创新药指数上涨3.78%，港股创新药指数上涨5.32%。创新药有“泡沫”？他表示，他管理的组合过往也持有创新药相关上市公司。从其一季报十大重仓股来看，创新药“华海药业”已退出十大重仓股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025061005154397785817&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025061005154397785817&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","BK1574","03692","09926","BK1583","06978","BK1161","BK1191"],"gpt_icon":0},{"id":"2542650355","title":"安士制药（中山）有限公司申请III类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2542650355","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542650355?lang=zh_cn&edition=fundamental","pubTime":"2025-06-10 07:03","pubTimestamp":1749510199,"startTime":"0","endTime":"0","summary":"金融界6月10日消息，据CDE官网沟通交流公示，于6月10日收到安士制药 有限公司申请的“III类会议”，当前状态“处理中”。安士制药（中山）有限公司，成立于2003年，位于中山市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，安士制药（中山）有限公司共对外投资了11家企业，参与招投标项目511次，知识产权方面有商标信息82条，专利信息54条，此外企业还拥有行政许可427个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/10070350958812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4134","BK1191","BK1574","III","01477"],"gpt_icon":0},{"id":"2542435807","title":"连云港职业技术学院打造智能制药人才新高地","url":"https://stock-news.laohu8.com/highlight/detail?id=2542435807","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542435807?lang=zh_cn&edition=fundamental","pubTime":"2025-06-10 05:50","pubTimestamp":1749505800,"startTime":"0","endTime":"0","summary":"在连云港市加快建设“中华药港”，生物医药产业成功获批国家先进制造业集群、正聚力向千亿产业集群奋进的浪潮中，连云港职业技术学院以“药品生产技术”江苏省高水平专业群为依托，构建“集群·互融·共生”的智能制药复合型高技能人才培养体系，推动人才培养与企业生产岗位“靶向对接”，打通企业科技成果转化和学校课程转化的“双转通道”，服务天晴药业、恒瑞药业等30余家企业，成为区域医药产业高质量发展的人才引擎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-06-10/doc-inezpqhw9372710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["601008","BK1191","BK0047","BK1574","BK0270","BK0000","01477"],"gpt_icon":0},{"id":"2542360863","title":"【新股IPO】广州银诺医药集团股份有限公司向港交所主板提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2542360863","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542360863?lang=zh_cn&edition=fundamental","pubTime":"2025-06-10 00:14","pubTimestamp":1749485695,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所6月9日披露，广州银诺医药集团股份有限公司向港交所主板提交上市申请，中信证券、中金公司为联席保荐人。自2014年成立以来，公司已建立了针对糖尿病和其他代谢性疾病的候选药物管线。公司于2025年1月在中国成功获得用于治疗2型糖尿病的依苏帕格鲁肽α的监管批准。财务方面，于2022年、2024年截至12月31日止年度，公司研发开支约为4.92亿元、1.03亿元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20220324/YTNhZjA5ZTE4MjQwNDU0MzY1MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/YTNhZjA5ZTE4MjQwNDU0MzY1MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1960128","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1515","BK1161","HEXmain","159938","BK1574"],"gpt_icon":0},{"id":"2542733931","title":"紧跟医药新零售， 药师帮抢先布局“AI、机器人”医药场景","url":"https://stock-news.laohu8.com/highlight/detail?id=2542733931","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542733931?lang=zh_cn&edition=fundamental","pubTime":"2025-06-10 00:10","pubTimestamp":1749485419,"startTime":"0","endTime":"0","summary":"6月3日，药师帮与越疆达成战略合作，双方将围绕协作机器人及AI产品在医药领域的应用展开深度合作。同时，紧跟未来药店业态升级趋势，公司近期入局医药机器人及AI大模型领域。6月3日，药师帮宣布与协作机器人龙头越疆科技达成战略合作，以医药协作机器人、AI大模型、药品物联网三大技术切入新零售场景，进一步发掘面向零售药店的高附加值业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025061000112897780e84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025061000112897780e84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","BK1197","BK1161","09939","09885"],"gpt_icon":0},{"id":"2542033659","title":"万春医药上涨22.88%，报2.089美元/股，总市值8422.08万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542033659","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542033659?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 23:31","pubTimestamp":1749483080,"startTime":"0","endTime":"0","summary":"6月9日，万春医药盘中上涨22.88%，截至23:31，报2.089美元/股，成交4.61万美元，总市值8422.08万美元。财务数据显示，截至2024年06月30日，万春医药收入总额100.0万美元，同比增长14.29%；归母净利润-726.2万美元，同比增长42.91%。大事提醒：5月5日，万春医药将披露2024财年年报。资料显示，万春药业公司是一家处于全球临床阶段的生物制药公司,专注于新型癌症疗法,包括晚期肿瘤免疫药物的研发。公司成立于2013年,总部设立在美国。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/09233150957571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159938","09939","BK1161","BK1574","BK1515"],"gpt_icon":0},{"id":"2542333097","title":"中国抗体-B(03681)：独立非执行董事Dylan Carlo TINKER离世","url":"https://stock-news.laohu8.com/highlight/detail?id=2542333097","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542333097?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 22:54","pubTimestamp":1749480862,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B(03681)发布公告，公司的独立非执行董事、审核委员会成员及提名委员会成员Dylan Carlo TINKER于2025年5月29日离世。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1303189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","03681"],"gpt_icon":0},{"id":"2542338986","title":"美股异动 | 百济神州(ONC.US)涨逾4% 机构：创新药有望迎来价值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2542338986","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542338986?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 21:59","pubTimestamp":1749477574,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，百济神州(ONC.US)涨逾4%，报267.04美元。消息面上，近期，ASCO正式召开，ASCO是全球肿瘤学领域规模最大、学术影响力最高的会议。ASCO报告上展示信达生物的IBI363(PD-1/IL2α双抗)在结直肠癌和IO经治非小细胞肺癌上展现出优异疗效，同时泽璟制药ZG005治疗宫颈癌数据、荣昌生物的RC108(c-MET ADC)等也有较好的数据展示。兴业证券表示，中国创新药具备高效率、低成本的开发优势，当前在热门技术赛道如ADC、双抗、细胞治疗等已经具备竞争优势，有望持续展现行业竞争力。机构分析认为，展望未来，创新药有望迎来价值重估。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1303170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1583","688235","BK1588","LU0588546209.SGD","LU1969619763.USD","LU2328871848.SGD","06160","BK1161","BK1500","ONC","BK4526","LU0307460666.USD","BK0239","159992","BK4139","BK1574"],"gpt_icon":0},{"id":"2542380307","title":"恒瑞医药HER2 ADC创新药注射用瑞康曲妥珠单抗全国首批发货","url":"https://stock-news.laohu8.com/highlight/detail?id=2542380307","media":"恒瑞医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542380307?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 21:27","pubTimestamp":1749475632,"startTime":"0","endTime":"0","summary":"2025年6月8日，恒瑞医药子公司苏州盛迪亚生物医药有限公司自主研发的1类新药注射用瑞康曲妥珠单抗（艾维达）首批发货仪式在苏州盛迪亚生产基地隆重举行，这是国内首个获批用于HER2突变NSCLC患者的中国自主研发抗体偶联药物，首批药品将迅速覆盖全国多个医疗机构，为广大患者带来精准治疗的新希望。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609212905a4a079be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609212905a4a079be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","06978","BK1574","BK1161","BK1191","600276"],"gpt_icon":1},{"id":"2542387603","title":"创新药持续火爆，“吃药”行情后市怎么看？","url":"https://stock-news.laohu8.com/highlight/detail?id=2542387603","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542387603?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 21:11","pubTimestamp":1749474679,"startTime":"0","endTime":"0","summary":"创新药板块再度走强。6月9日，常山药业（300255.SZ）、舒泰神（300204.SZ）、睿智医药（300149.SZ）、众生药业（002317.SZ）等多只A股涨停。港股的金斯瑞生物科技（01548.HK）、四环医药（00460.HK）、诺诚健华（09969.HK）等大涨超10%。记者注意到，这轮\"吃药\"行情与过往不同，涨幅龙头集中于创新药企业，且港股表现尤为强劲。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202506093425677228.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202506093425677228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1574","BK1161"],"gpt_icon":0},{"id":"2542464380","title":"争议最大的国产创新药九期一，已经停工停产","url":"https://stock-news.laohu8.com/highlight/detail?id=2542464380","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542464380?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 20:58","pubTimestamp":1749473880,"startTime":"0","endTime":"0","summary":"　　6月8日，据第一财经报道，绿谷医药科技 已经停产甘露特钠胶囊，公司将关闭相关办公区、生产区。　　但是尽管如此，相关的各种质疑一直未曾间断，这款药物可以说是中国医药发展历史上，目前为止争议最大的一款创新药。　　有业内人士指出，制药企业通常会在许可批件到期前6个月申请延续，而许可证过期尚未获得新一轮审批通过导致停工停产的情况“并不常见”。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/med/2025-06-09/doc-ineznxme9701651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","159992","BK1161","BK1574"],"gpt_icon":0},{"id":"2542730384","title":"6月9日鹏华医药科技股票A净值增长5.27%，今年来累计上涨64.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542730384","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542730384?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 20:20","pubTimestamp":1749471610,"startTime":"0","endTime":"0","summary":"金融界2025年6月9日消息，鹏华医药科技股票A 最新净值1.6590元，增长5.27%。该基金近1个月收益率22.88%，同类排名7|660；近6个月收益率49.92%，同类排名3|640；今年来收益率64.80%，同类排名3|646。公开资料显示，鹏华医药科技股票A基金成立于2015年6月2日，截至2025年3月31日，鹏华医药科技股票A规模19.49亿元，基金经理为金笑非。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/09202050955411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","BK1574","159938","09939","BK1161"],"gpt_icon":0},{"id":"2542846903","title":"A股创新药板块走强 产业或迎爆发式增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2542846903","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542846903?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 20:10","pubTimestamp":1749471049,"startTime":"0","endTime":"0","summary":"6月9日，化学制品、医疗服务、生物制品、中药、医药商业多个板块联动效应明显。概念板块中，减肥药、创新药、阿兹海默、肝素概念集体飘红，引发市场对医药行业基本面的广泛关注。中国金融智库特邀研究员余丰慧向《证券日报》记者表示，这主要受到几方面因素的驱动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202506093425626020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06978","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":34,"pageCount":4,"totalSize":674,"code":"91000000","status":"200"}]}}